Table 1.
Study timeline
| Day | −3 or −2 | 0 | 3 | 7 (±1) | 15 (±3) | 30 (±5) | 60 (±7) | 90 (±7) |
|---|---|---|---|---|---|---|---|---|
| Recruitment |
√ |
|
|
|
|
|
|
|
| Informed consent |
√ |
|
|
|
|
|
|
|
| Selection criteria |
√ |
|
|
|
|
|
|
|
| Medical history |
√ |
|
|
|
|
|
|
|
| Physical examination |
√ |
|
|
|
|
|
|
√ |
| Blood samples for pharmacogenetics |
√ |
|
|
|
|
|
|
|
| Randomization |
√ |
|
|
|
|
|
|
|
| Acenocoumarol dosing (initiation/adjustment)a |
|
√ |
√ |
√ |
√ |
√ |
√ |
√ |
| INR determination |
|
√ |
√ |
√ |
√ |
√ |
√ |
√ |
| Evaluation of side effects | √ | √ | √ | √ | √ | √ | √ |
aIn order to perform appropriate dose adjustments, additional visits can be scheduled as needed, at the discretion of the clinical researcher.